S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Editas Medicine Stock Forecast, Price & News

+0.76 (+6.42%)
(As of 07/1/2022 08:44 PM ET)
Today's Range
50-Day Range
52-Week Range
1.44 million shs
Average Volume
1.81 million shs
Market Capitalization
$864.19 million
P/E Ratio
Dividend Yield
Price Target

Editas Medicine MarketRank™ Forecast

Analyst Rating
2.22 Rating Score
163.7% Upside
$33.20 Price Target
Short Interest
21.30% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Selling Shares
$86.23 K Sold Last Quarter
Proj. Earnings Growth
From ($3.41) to ($3.38) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.24 out of 5 stars

Medical Sector

230th out of 1,412 stocks

Biological Products, Except Diagnostic Industry

30th out of 215 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Editas Medicine logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock News Headlines

Editas Medicine (NASDAQ:EDIT) Stock Price Down 8%
Editas Medicine Tops Q1 EPS by 5c
Editas Medicine Q1 2022 Earnings Preview
Expert Ratings For Editas Medicine
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$-192.50 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$25.54 million
Book Value
$8.09 per share


Free Float
Market Cap
$864.19 million

Editas Medicine Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2022?

9 analysts have issued 1-year target prices for Editas Medicine's stock. Their EDIT stock forecasts range from $8.00 to $80.00. On average, they anticipate Editas Medicine's share price to reach $33.20 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price.
View analysts' price targets for Editas Medicine
or view top-rated stocks among Wall Street analysts.

How has Editas Medicine's stock performed in 2022?

Editas Medicine's stock was trading at $26.55 at the beginning of 2022. Since then, EDIT stock has decreased by 52.6% and is now trading at $12.59.
View the best growth stocks for 2022 here

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Editas Medicine

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, May, 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.07. The company earned $6.80 million during the quarter, compared to analysts' expectations of $3.85 million. Editas Medicine had a negative trailing twelve-month return on equity of 32.88% and a negative net margin of 721.60%. The company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.86) earnings per share.
View Editas Medicine's earnings history

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Mr. James C. Mullen, Exec. Chairman (Age 63, Pay $1.01M) (LinkedIn Profile)
  • Ms. Michelle Robertson, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 55, Pay $641.74k)
  • Dr. Mark S. Shearman, Exec. VP & Chief Scientific Officer (Age 62, Pay $639.89k)
  • Dr. Bruce E. Eaton Ph.D., Exec. VP & Chief Bus. Officer (Age 68, Pay $1.09M)
  • Dr. Gilmore O'Neill, Pres & CEO (Age 58)
  • Dr. Feng Zhang Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D., Co-Founder & Scientific Advisory Board Member (Age 68)
  • Dr. J. Keith Joung M.D., Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D., Co-Founder & Scientific Advisory Board Member
  • Mr. Harry R. Gill III, Sr. VP of Operations (Age 61)

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $12.59.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $864.19 million and generates $25.54 million in revenue each year. The company earns $-192.50 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for Editas Medicine is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.